<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Early Risk Assessment for AMD | A1 Diagnosis</title>
    <meta name="description" content="Discover how early risk assessment using biomarkers, AI screening, and blood-based testing can detect AMD risk before vision loss occurs. Based on NIH and NEI research.">

    <link rel="icon" type="image/png" href="A1_Favicon_V2.png">
    <link rel="shortcut icon" type="image/png" href="A1_Favicon_V2.png">

    <!-- Google tag (gtag.js) -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=G-27QM6KXY13"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());
      gtag('config', 'G-27QM6KXY13');
    </script>

    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700;800&display=swap" rel="stylesheet">

    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        html {
            scroll-behavior: smooth;
        }

        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
            line-height: 1.7;
            color: #475569;
            background: #ffffff;
        }

        /* --- NAVBAR --- */
        .navbar {
            background: rgba(255, 255, 255, 0.98);
            border-bottom: 1px solid #e5e7eb;
            padding: 1rem 0;
            position: sticky;
            top: 0;
            z-index: 1000;
            box-shadow: 0 1px 3px rgba(0,0,0,0.05);
        }

        .nav-content {
            max-width: 1200px;
            margin: 0 auto;
            padding: 0 24px;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        .logo {
            display: flex;
            align-items: center;
            gap: 12px;
            font-size: 24px;
            font-weight: 800;
            letter-spacing: -0.5px;
            color: #000000;
            text-decoration: none;
        }

        .logo-image {
            height: 40px;
            width: auto;
        }

        .nav-back {
            color: #64748b;
            text-decoration: none;
            font-weight: 500;
            font-size: 0.9rem;
            transition: color 0.3s;
        }

        .nav-back:hover {
            color: #0ea5e9;
        }

        /* --- HERO --- */
        .hero {
            background: linear-gradient(135deg, #3b82f6 0%, #1d4ed8 50%, #1e40af 100%);
            color: white;
            padding: 60px 24px;
            text-align: center;
        }

        .hero h1 {
            font-size: 2.5rem;
            font-weight: 800;
            margin-bottom: 16px;
            letter-spacing: -0.5px;
        }

        .hero p {
            font-size: 1.15rem;
            opacity: 0.9;
            max-width: 700px;
            margin: 0 auto;
            font-weight: 400;
        }

        /* --- PAGE NAV TABS --- */
        .page-nav {
            background: #ffffff;
            border-bottom: 1px solid #e5e7eb;
            position: sticky;
            top: 65px;
            z-index: 999;
            box-shadow: 0 2px 8px rgba(0,0,0,0.04);
        }

        .page-nav-inner {
            max-width: 1200px;
            margin: 0 auto;
            padding: 0 24px;
            display: flex;
            gap: 0;
        }

        .page-nav a {
            display: block;
            padding: 16px 24px;
            text-decoration: none;
            color: #64748b;
            font-weight: 500;
            font-size: 0.95rem;
            border-bottom: 3px solid transparent;
            transition: all 0.3s;
            white-space: nowrap;
        }

        .page-nav a:hover {
            color: #0d9488;
            background: #f0fdfa;
        }

        .page-nav a.active {
            color: #0d9488;
            border-bottom-color: #14b8a6;
            font-weight: 600;
        }

        /* --- MAIN CONTENT --- */
        .main-content {
            max-width: 860px;
            margin: 0 auto;
            padding: 48px 24px 64px;
        }

        .section {
            margin-bottom: 48px;
        }

        .section h2 {
            font-size: 1.75rem;
            font-weight: 700;
            color: #1e293b;
            margin-bottom: 16px;
            letter-spacing: -0.3px;
        }

        .section h3 {
            font-size: 1.25rem;
            font-weight: 600;
            color: #1e293b;
            margin-bottom: 12px;
        }

        .section p {
            margin-bottom: 16px;
            font-size: 1.05rem;
        }

        .section ul, .section ol {
            margin-bottom: 16px;
            padding-left: 24px;
        }

        .section li {
            margin-bottom: 8px;
            font-size: 1.05rem;
        }

        /* --- INFO BOX --- */
        .info-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
            padding: 20px 24px;
            border-radius: 0 12px 12px 0;
            margin: 24px 0;
        }

        .info-box p {
            margin-bottom: 0;
            color: #1e40af;
            font-weight: 500;
        }

        .info-box a {
            color: #1e40af;
        }

        /* --- ALERT BOX --- */
        .alert-box {
            background: #fef3c7;
            border-left: 4px solid #f59e0b;
            padding: 20px 24px;
            border-radius: 0 12px 12px 0;
            margin: 24px 0;
        }

        .alert-box p {
            margin-bottom: 0;
            color: #92400e;
            font-weight: 500;
        }

        .alert-box strong {
            color: #78350f;
        }

        /* --- HIGHLIGHT BOX --- */
        .highlight-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
            padding: 24px 28px;
            border-radius: 0 12px 12px 0;
            margin: 24px 0;
        }

        .highlight-box h3 {
            color: #0f766e;
            margin-bottom: 12px;
        }

        .highlight-box ul {
            padding-left: 20px;
        }

        .highlight-box li {
            color: #115e59;
            margin-bottom: 6px;
        }

        /* --- QUOTE BOX --- */
        .quote-box {
            background: linear-gradient(135deg, #f0fdfa, #f0f9ff);
            border-left: 4px solid #14b8a6;
            padding: 24px 28px;
            border-radius: 0 12px 12px 0;
            margin: 24px 0;
            font-style: italic;
        }

        .quote-box p {
            color: #0f766e;
            font-size: 1.1rem;
            margin-bottom: 8px;
        }

        .quote-box .quote-source {
            font-style: normal;
            font-size: 0.85rem;
            color: #64748b;
            font-weight: 500;
        }

        .quote-box .quote-source a {
            color: #0284c7;
            text-decoration: none;
        }

        .quote-box .quote-source a:hover {
            text-decoration: underline;
        }

        /* --- CONTENT CARDS --- */
        .card-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 24px;
            margin: 24px 0;
        }

        .card {
            background: #ffffff;
            border: 1px solid #e5e7eb;
            border-radius: 16px;
            padding: 28px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.06), 0 4px 12px rgba(0,0,0,0.04);
            transition: transform 0.3s, box-shadow 0.3s;
        }

        .card:hover {
            transform: translateY(-2px);
            box-shadow: 0 4px 12px rgba(0,0,0,0.1), 0 8px 24px rgba(0,0,0,0.06);
        }

        .card h3 {
            font-size: 1.2rem;
            margin-bottom: 12px;
        }

        .card p, .card li {
            font-size: 0.98rem;
        }

        .card.teal-top { border-top: 4px solid #14b8a6; }
        .card.blue-top { border-top: 4px solid #3b82f6; }
        .card.amber-top { border-top: 4px solid #f59e0b; }
        .card.green-top { border-top: 4px solid #22c55e; }

        .card.teal-top h3 { color: #0f766e; }
        .card.blue-top h3 { color: #1d4ed8; }
        .card.amber-top h3 { color: #b45309; }
        .card.green-top h3 { color: #16a34a; }

        /* --- APPROACH CARDS (3 columns) --- */
        .approach-grid {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 24px;
            margin: 24px 0;
        }

        .approach-card {
            background: #ffffff;
            border: 1px solid #e5e7eb;
            border-radius: 16px;
            padding: 28px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.06), 0 4px 12px rgba(0,0,0,0.04);
            transition: transform 0.3s, box-shadow 0.3s;
            text-align: center;
        }

        .approach-card:hover {
            transform: translateY(-2px);
            box-shadow: 0 4px 12px rgba(0,0,0,0.1), 0 8px 24px rgba(0,0,0,0.06);
        }

        .approach-card:nth-child(1) { border-top: 4px solid #3b82f6; }
        .approach-card:nth-child(2) { border-top: 4px solid #14b8a6; }
        .approach-card:nth-child(3) { border-top: 4px solid #22c55e; }

        .approach-icon {
            font-size: 2.5rem;
            margin-bottom: 16px;
            line-height: 1;
        }

        .approach-card h3 {
            font-size: 1.1rem;
            margin-bottom: 10px;
            color: #1e293b;
        }

        .approach-card p {
            font-size: 0.95rem;
            margin-bottom: 0;
        }

        /* --- BIOMARKER TABLE --- */
        .styled-table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin: 24px 0;
            border-radius: 12px;
            overflow: hidden;
            box-shadow: 0 1px 3px rgba(0,0,0,0.06), 0 4px 12px rgba(0,0,0,0.04);
        }

        .styled-table thead th {
            background: linear-gradient(135deg, #3b82f6 0%, #1d4ed8 100%);
            color: white;
            padding: 14px 20px;
            text-align: left;
            font-weight: 600;
            font-size: 0.95rem;
        }

        .styled-table tbody td {
            padding: 14px 20px;
            border-bottom: 1px solid #f1f5f9;
            font-size: 0.95rem;
        }

        .styled-table tbody tr:nth-child(even) {
            background: #f8fafc;
        }

        .styled-table tbody tr:hover {
            background: #f0f9ff;
        }

        .styled-table tbody tr:last-child td {
            border-bottom: none;
        }

        /* --- METRIC CARDS --- */
        .metric-grid {
            display: grid;
            grid-template-columns: repeat(4, 1fr);
            gap: 20px;
            margin: 24px 0;
        }

        .metric-card {
            background: #ffffff;
            border: 1px solid #e5e7eb;
            border-radius: 16px;
            padding: 24px 16px;
            text-align: center;
            box-shadow: 0 1px 3px rgba(0,0,0,0.06), 0 4px 12px rgba(0,0,0,0.04);
            transition: transform 0.3s, box-shadow 0.3s;
        }

        .metric-card:hover {
            transform: translateY(-2px);
            box-shadow: 0 4px 12px rgba(0,0,0,0.1), 0 8px 24px rgba(0,0,0,0.06);
        }

        .metric-card:nth-child(1) { border-top: 4px solid #3b82f6; }
        .metric-card:nth-child(2) { border-top: 4px solid #14b8a6; }
        .metric-card:nth-child(3) { border-top: 4px solid #f59e0b; }
        .metric-card:nth-child(4) { border-top: 4px solid #22c55e; }

        .metric-value {
            font-size: 1.8rem;
            font-weight: 800;
            letter-spacing: -0.5px;
            margin-bottom: 8px;
            line-height: 1.2;
        }

        .metric-card:nth-child(1) .metric-value { background: linear-gradient(135deg, #3b82f6, #1d4ed8); -webkit-background-clip: text; -webkit-text-fill-color: transparent; background-clip: text; }
        .metric-card:nth-child(2) .metric-value { background: linear-gradient(135deg, #14b8a6, #0d9488); -webkit-background-clip: text; -webkit-text-fill-color: transparent; background-clip: text; }
        .metric-card:nth-child(3) .metric-value { background: linear-gradient(135deg, #f59e0b, #d97706); -webkit-background-clip: text; -webkit-text-fill-color: transparent; background-clip: text; }
        .metric-card:nth-child(4) .metric-value { background: linear-gradient(135deg, #22c55e, #16a34a); -webkit-background-clip: text; -webkit-text-fill-color: transparent; background-clip: text; }

        .metric-label {
            font-size: 0.85rem;
            color: #64748b;
            font-weight: 500;
        }

        /* --- TIMELINE --- */
        .timeline {
            position: relative;
            padding-left: 32px;
            margin: 24px 0;
        }

        .timeline::before {
            content: '';
            position: absolute;
            left: 10px;
            top: 0;
            bottom: 0;
            width: 3px;
            background: linear-gradient(to bottom, #3b82f6, #14b8a6, #22c55e);
            border-radius: 3px;
        }

        .timeline-item {
            position: relative;
            margin-bottom: 28px;
            padding: 20px 24px;
            background: #ffffff;
            border: 1px solid #e5e7eb;
            border-radius: 12px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.06);
        }

        .timeline-item::before {
            content: '';
            position: absolute;
            left: -27px;
            top: 24px;
            width: 12px;
            height: 12px;
            border-radius: 50%;
            background: #3b82f6;
            border: 3px solid #ffffff;
            box-shadow: 0 0 0 2px #3b82f6;
        }

        .timeline-item:nth-child(2)::before { background: #14b8a6; box-shadow: 0 0 0 2px #14b8a6; }
        .timeline-item:nth-child(3)::before { background: #22c55e; box-shadow: 0 0 0 2px #22c55e; }

        .timeline-item h3 {
            font-size: 1.1rem;
            margin-bottom: 8px;
            color: #1e293b;
        }

        .timeline-item p {
            font-size: 0.98rem;
            margin-bottom: 0;
        }

        /* --- RESOURCES --- */
        .resource-links {
            list-style: none;
            padding-left: 0;
        }

        .resource-links li {
            margin-bottom: 12px;
        }

        .resource-links a {
            color: #0284c7;
            text-decoration: none;
            font-weight: 500;
            font-size: 1.05rem;
            transition: color 0.3s;
        }

        .resource-links a:hover {
            color: #0369a1;
            text-decoration: underline;
        }

        .resource-links .resource-desc {
            display: block;
            color: #64748b;
            font-size: 0.9rem;
            font-weight: 400;
            margin-top: 2px;
        }

        /* --- CTA SECTION --- */
        .cta-section {
            background: linear-gradient(135deg, #eff6ff, #f0fdfa);
            border: 1px solid #bfdbfe;
            border-radius: 20px;
            padding: 40px 36px;
            text-align: center;
            margin: 48px 0;
        }

        .cta-section h2 {
            color: #1d4ed8;
            margin-bottom: 12px;
        }

        .cta-section p {
            max-width: 600px;
            margin: 0 auto 24px;
        }

        .cta-links {
            display: flex;
            gap: 16px;
            justify-content: center;
            flex-wrap: wrap;
        }

        .cta-link {
            display: inline-block;
            padding: 12px 28px;
            border-radius: 10px;
            text-decoration: none;
            font-weight: 600;
            font-size: 0.95rem;
            transition: transform 0.3s, box-shadow 0.3s;
        }

        .cta-link:hover {
            transform: translateY(-2px);
            box-shadow: 0 4px 12px rgba(0,0,0,0.15);
        }

        .cta-link.primary {
            background: linear-gradient(135deg, #3b82f6, #1d4ed8);
            color: white;
        }

        .cta-link.secondary {
            background: white;
            color: #1d4ed8;
            border: 2px solid #3b82f6;
        }

        /* --- FOOTER --- */
        .footer {
            background: #1e293b;
            color: #94a3b8;
            padding: 48px 24px 32px;
            margin-top: 64px;
        }

        .footer-inner {
            max-width: 1200px;
            margin: 0 auto;
        }

        .footer-links {
            display: flex;
            gap: 24px;
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .footer-links a {
            color: #cbd5e1;
            text-decoration: none;
            font-size: 0.9rem;
            transition: color 0.3s;
        }

        .footer-links a:hover {
            color: #14b8a6;
        }

        .footer-disclaimer {
            font-size: 0.8rem;
            line-height: 1.6;
            color: #64748b;
            border-top: 1px solid #334155;
            padding-top: 24px;
            margin-top: 24px;
        }

        .footer-copyright {
            font-size: 0.85rem;
            margin-bottom: 16px;
        }

        /* --- RESPONSIVE --- */
        @media (max-width: 768px) {
            .hero {
                padding: 40px 20px;
            }

            .hero h1 {
                font-size: 1.75rem;
            }

            .hero p {
                font-size: 1rem;
            }

            .page-nav-inner {
                flex-direction: column;
                padding: 8px 0;
            }

            .page-nav a {
                padding: 12px 24px;
                border-bottom: none;
                border-left: 3px solid transparent;
                font-size: 0.9rem;
            }

            .page-nav a.active {
                border-bottom: none;
                border-left-color: #14b8a6;
                background: #f0fdfa;
            }

            .card-grid,
            .approach-grid {
                grid-template-columns: 1fr;
            }

            .metric-grid {
                grid-template-columns: 1fr 1fr;
            }

            .main-content {
                padding: 32px 20px 48px;
            }

            .section h2 {
                font-size: 1.4rem;
            }

            .styled-table thead th,
            .styled-table tbody td {
                padding: 10px 12px;
                font-size: 0.85rem;
            }

            .metric-value {
                font-size: 1.5rem;
            }

            .cta-section {
                padding: 28px 20px;
            }

            .cta-links {
                flex-direction: column;
                align-items: center;
            }

            .footer-links {
                flex-direction: column;
                gap: 12px;
            }
        }

        @media (max-width: 480px) {
            .metric-grid {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>
<body>

    <!-- NAVBAR -->
    <nav class="navbar">
        <div class="nav-content">
            <a href="index.html" class="logo">
                <img src="A1_Diagnosis_Logo.jpg" alt="A1 Diagnosis Logo" class="logo-image">
            </a>
            <a href="index.html" class="nav-back">&larr; Back to Home</a>
        </div>
    </nav>

    <!-- HERO -->
    <header class="hero">
        <h1>Early Risk Assessment</h1>
        <p>How biomarkers, AI, and blood-based screening are enabling detection of AMD risk before vision loss occurs</p>
    </header>

    <!-- PAGE NAV -->
    <nav class="page-nav">
        <div class="page-nav-inner">
            <a href="what-is-proactive-health.html">Proactive Health Care</a>
            <a href="early-risk-assessment.html" class="active">Early Risk Assessment</a>
            <a href="what-is-amd.html">What is AMD?</a>
            <a href="amd-stages.html">AMD Stages &amp; Treatments</a>
            <a href="risk-factors.html">Risk Factors &amp; Prevention</a>
        </div>
    </nav>

    <!-- MAIN CONTENT -->
    <main class="main-content">

        <!-- Section 1: Why Early Risk Assessment Matters -->
        <div class="section">
            <h2>Why Early Risk Assessment Matters</h2>
            <p>Age-Related Macular Degeneration (AMD) is the leading cause of severe, irreversible vision loss in adults over 35. Yet in its early stages, AMD has <strong>no noticeable symptoms</strong>. Most people are unaware they have the disease until significant damage has already occurred.</p>
            <p>Early risk assessment aims to change this by identifying individuals at elevated risk <em>before</em> symptoms develop&mdash;allowing for earlier monitoring, lifestyle interventions, and treatments that can slow or prevent disease progression.</p>

            <div class="quote-box">
                <p>&ldquo;Early detection and treatment can help protect vision and prevent vision loss. Many eye diseases have no early symptoms. But regular comprehensive dilated eye exams can help adults protect their vision by catching eye diseases and conditions early, when they&rsquo;re easier to treat.&rdquo;</p>
                <span class="quote-source">&mdash; <a href="https://www.nei.nih.gov/learn-about-eye-health/healthy-vision/get-dilated-eye-exam" target="_blank" rel="noopener">National Eye Institute (NEI)</a></span>
            </div>

            <div class="metric-grid">
                <div class="metric-card">
                    <div class="metric-value">20M+</div>
                    <div class="metric-label">Americans living with AMD</div>
                </div>
                <div class="metric-card">
                    <div class="metric-value">Zero</div>
                    <div class="metric-label">Symptoms in early AMD</div>
                </div>
                <div class="metric-card">
                    <div class="metric-value">10&ndash;20%</div>
                    <div class="metric-label">Progress to legally blind in &lt;5 years</div>
                </div>
                <div class="metric-card">
                    <div class="metric-value">~25%</div>
                    <div class="metric-label">Risk reduction with early intervention</div>
                </div>
            </div>
        </div>

        <!-- Section 2: Three Approaches to Risk Assessment -->
        <div class="section">
            <h2>Three Approaches to AMD Risk Assessment</h2>
            <p>According to NIH and NEI research, there are three complementary approaches to assessing AMD risk:</p>

            <div class="approach-grid">
                <div class="approach-card">
                    <div class="approach-icon">&#x1F9EA;</div>
                    <h3>Blood-Based Biomarkers</h3>
                    <p>Measuring proteins, metabolites, and molecular signals in a blood sample that correlate with AMD risk and progression</p>
                </div>
                <div class="approach-card">
                    <div class="approach-icon">&#x1F441;</div>
                    <h3>Structural Imaging</h3>
                    <p>OCT scans, fundus photography, and adaptive optics to detect drusen, pigment changes, and retinal thinning</p>
                </div>
                <div class="approach-card">
                    <div class="approach-icon">&#x1F916;</div>
                    <h3>AI-Powered Screening</h3>
                    <p>Machine learning models that analyze retinal images and patient data to predict who is at highest risk of rapid progression</p>
                </div>
            </div>

            <div class="info-box">
                <p>NIH researchers conclude that a multimodal approach&mdash;combining structural, functional, and systemic biomarker measurements&mdash;provides superior prognostic accuracy compared to any single method alone. &mdash; <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10640447/" target="_blank" rel="noopener">PMC</a></p>
            </div>
        </div>

        <!-- Section 3: Blood-Based Biomarkers -->
        <div class="section">
            <h2>Blood-Based Biomarkers for AMD</h2>
            <p>Research published through the National Institutes of Health has identified several blood-based biomarkers associated with AMD risk and progression. While evidence is still developing, these markers represent a promising frontier for non-invasive early screening:</p>

            <table class="styled-table">
                <thead>
                    <tr>
                        <th>Biomarker</th>
                        <th>Finding</th>
                        <th>Significance</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Apolipoprotein M (ApoM)</strong></td>
                        <td>Reduced levels in AMD patients vs. healthy controls</td>
                        <td>Links AMD to cholesterol metabolism dysfunction; potential therapeutic target</td>
                    </tr>
                    <tr>
                        <td><strong>C-Reactive Protein (CRP)</strong></td>
                        <td>Elevated levels associated with late AMD progression</td>
                        <td>Systemic inflammation marker; increased risk indicator</td>
                    </tr>
                    <tr>
                        <td><strong>HDL Cholesterol</strong></td>
                        <td>Elevated HDL-C predicts AMD progression</td>
                        <td>Lipid metabolism involvement in retinal disease</td>
                    </tr>
                    <tr>
                        <td><strong>Homocysteine</strong></td>
                        <td>Elevated serum levels correlate with wet and dry AMD severity</td>
                        <td>Established biomarker for AMD; measurable in routine blood tests</td>
                    </tr>
                    <tr>
                        <td><strong>Interleukin-6 (IL-6)</strong></td>
                        <td>Associated with advanced AMD</td>
                        <td>Inflammatory pathway involvement in disease progression</td>
                    </tr>
                    <tr>
                        <td><strong>Interleukin-8 (IL-8)</strong></td>
                        <td>Associated with advanced AMD</td>
                        <td>Immune-mediated retinal damage marker</td>
                    </tr>
                    <tr>
                        <td><strong>8 Metabolite Panel</strong></td>
                        <td>Significant association with 3-year AMD progression</td>
                        <td>Multi-metabolite approach improves predictive accuracy</td>
                    </tr>
                </tbody>
            </table>

            <div class="quote-box">
                <p>&ldquo;Patients with macular degeneration have reduced levels of ApoM circulating in the blood compared with healthy controls. Various methods of dialing up ApoM could serve as new treatment strategies for AMD.&rdquo;</p>
                <span class="quote-source">&mdash; <a href="https://www.nei.nih.gov/research-and-training/research-news/strategy-prevent-age-related-macular-degeneration-identified" target="_blank" rel="noopener">National Eye Institute, 2025</a></span>
            </div>
        </div>

        <!-- Section 4: Genetic Risk Factors -->
        <div class="section">
            <h2>Genetic Risk Factors</h2>
            <p>Research has identified significant genetic components to AMD risk. According to NIH studies, <strong>52 common and rare single nucleotide polymorphisms (SNPs) across 34 genetic loci</strong> are associated with AMD:</p>

            <div class="card-grid">
                <div class="card blue-top">
                    <h3>Key Genetic Variants</h3>
                    <ul>
                        <li><strong>Complement Factor H (CFH)</strong> &mdash; Captures a substantial fraction of AMD risk</li>
                        <li><strong>PLEKHA1/ARMS2/HtrA1</strong> &mdash; Among the strongest genetic predictors</li>
                        <li><strong>VEGF SNPs</strong> &mdash; Vascular endothelial growth factor variants linked to wet AMD</li>
                        <li><strong>Complement Factor B and C2</strong> &mdash; Promising markers in the complement pathway</li>
                    </ul>
                </div>
                <div class="card amber-top">
                    <h3>NEI Position on Genetic Testing</h3>
                    <p>The National Eye Institute currently does <strong>not recommend</strong> genetic testing for AMD in clinical practice because:</p>
                    <ul>
                        <li>Results cannot reliably guide prevention or treatment decisions</li>
                        <li>AMD involves many known and yet-undiscovered genetic factors</li>
                        <li>Even when weighted with other risk factors, genetic status fails to reliably predict individual risk</li>
                    </ul>
                    <p>Genetic markers remain valuable for <strong>research purposes</strong> and stratifying patients into risk categories in clinical trials.</p>
                </div>
            </div>

            <div class="info-box">
                <p>While genetic testing alone is insufficient, combining genetic data with blood-based biomarkers and clinical assessments may provide a more complete picture of individual AMD risk in the future. &mdash; <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2000850/" target="_blank" rel="noopener">PMC</a></p>
            </div>
        </div>

        <!-- Section 5: AI-Powered Screening -->
        <div class="section">
            <h2>AI-Powered Screening for AMD</h2>
            <p>The National Eye Institute highlights artificial intelligence as a transformative tool for early AMD detection and risk prediction:</p>

            <div class="card-grid">
                <div class="card teal-top">
                    <h3>How AI Screening Works</h3>
                    <p>Deep convolutional neural networks are trained on large datasets of patients with known outcomes. The network extracts features from retinal images&mdash;such as drusen size, type, and pigment abnormalities&mdash;and combines them with patient data including age, smoking status, and genetic profile.</p>
                    <p>With enough data, the network detects patterns that enable both screening and prediction of progression.</p>
                </div>
                <div class="card green-top">
                    <h3>Why It Matters</h3>
                    <p>For <strong>10&ndash;20% of AMD patients</strong>, disease progresses from diagnosis to late-stage and legally blind in under 5 years. The NEI notes that identifying who falls into this high-risk group &ldquo;often isn&rsquo;t easy&rdquo; with traditional methods.</p>
                    <p>AI systems like <strong>iPredict</strong> enable non-eye-care specialists to screen patients and predict which individuals with early AMD are at risk for accelerated vision loss.</p>
                </div>
            </div>

            <div class="quote-box">
                <p>&ldquo;Emerging AI methods may be used to automatically detect and quantify AMD biomarkers in a cost-effective, rapid throughput manner. This will expedite screening and assist in the selection of appropriate patients for clinical trials.&rdquo;</p>
                <span class="quote-source">&mdash; <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10640447/" target="_blank" rel="noopener">National Institutes of Health, PMC</a></span>
            </div>
        </div>

        <!-- Section 6: NEI Advanced AMD Risk Calculator -->
        <div class="section">
            <h2>NEI Advanced AMD Risk Calculator</h2>
            <p>The National Eye Institute provides an <strong>Advanced AMD Risk Calculator</strong> for eye care professionals that predicts the likelihood of developing advanced AMD (geographic atrophy or neovascular AMD) over a period of 2 to 10 years.</p>

            <div class="timeline">
                <div class="timeline-item">
                    <h3>Who It Applies To</h3>
                    <p>Individuals aged 55&ndash;80 without advanced AMD in either eye, or with advanced AMD in only one eye. People older than 80 may use the calculator by entering 80 as their age.</p>
                </div>
                <div class="timeline-item">
                    <h3>How It Works</h3>
                    <p>The calculator generates group-based risk estimates based on patient characteristics. It predicts the proportion of patients sharing those characteristics who are likely to develop advanced AMD within a specified time interval.</p>
                </div>
                <div class="timeline-item">
                    <h3>Important Limitation</h3>
                    <p>Risk estimates apply to patient populations with similar characteristics&mdash;they cannot determine if or when a specific individual will develop advanced AMD. The calculator is intended for eye care professionals, not direct patient use.</p>
                </div>
            </div>

            <div class="info-box">
                <p>Source: <a href="https://www.nei.nih.gov/research/clinical-trials/advanced-amd-risk-calculator" target="_blank" rel="noopener">NEI Advanced AMD Risk Calculator</a> &mdash; National Eye Institute</p>
            </div>
        </div>

        <!-- Section 7: AMD Progression Risk -->
        <div class="section">
            <h2>Understanding AMD Progression Risk</h2>
            <p>Not all AMD progresses at the same rate. NIH research reveals important differences in progression risk depending on which eyes are affected:</p>

            <div class="card-grid">
                <div class="card blue-top">
                    <h3>Early AMD in One Eye Only</h3>
                    <p>For people with early AMD in one eye and no signs in the other, approximately <strong>5%</strong> will develop advanced AMD after 10 years.</p>
                </div>
                <div class="card amber-top">
                    <h3>Early AMD in Both Eyes</h3>
                    <p>For people with early AMD in both eyes, approximately <strong>14%</strong> will develop late AMD in at least one eye after 10 years.</p>
                </div>
            </div>

            <p>Research from PMC identifies that demographic, environmental, genetic, and molecular risk factors are <strong>most valuable at earlier disease stages</strong>, while phenotypic risk factors such as drusen and pigment abnormalities become more important for predicting progression during later stages of the disease.</p>

            <div class="alert-box">
                <p><strong>Critical window:</strong> For 10&ndash;20% of patients, AMD progresses from diagnosis to late-stage and legally blind in under 5 years. Identifying this high-risk group early is essential for timely intervention.</p>
            </div>
        </div>

        <!-- Section 8: The Future of Early Risk Assessment -->
        <div class="section">
            <h2>The Future of Early Risk Assessment</h2>
            <p>According to NIH research, the next generation of risk assessment tools will integrate multiple data sources for significantly improved predictive accuracy:</p>

            <ul>
                <li><strong>Blood-based biomarker panels</strong> &mdash; Multi-marker assays measuring inflammation, cholesterol metabolism, and complement activation from a simple blood draw</li>
                <li><strong>AI-integrated retinal imaging</strong> &mdash; Machine learning analysis of OCT and fundus images to detect subtle early changes invisible to the human eye</li>
                <li><strong>Genetic risk scoring</strong> &mdash; Polygenic risk scores combined with clinical data for improved stratification</li>
                <li><strong>Metabolomic profiling</strong> &mdash; Comprehensive analysis of blood metabolites to identify unique AMD risk signatures</li>
                <li><strong>Wearable monitoring</strong> &mdash; At-home vision monitoring devices and apps that detect early functional changes between office visits</li>
            </ul>

            <div class="quote-box">
                <p>&ldquo;Biomarker-based predictive models represent a paradigm shift from reactive medicine to proactive prevention. These systems enable early disease detection, risk stratification, and personalized interventions&mdash;foundational elements for evidence-based health management.&rdquo;</p>
                <span class="quote-source">&mdash; <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12399543/" target="_blank" rel="noopener">National Institutes of Health, PMC</a></span>
            </div>
        </div>

        <!-- Section 9: Key Takeaways -->
        <div class="section">
            <div class="highlight-box">
                <h3>Key Takeaways</h3>
                <ul>
                    <li>Early AMD has no symptoms&mdash;risk assessment tools are essential for detection before vision loss</li>
                    <li>Blood-based biomarkers including ApoM, CRP, homocysteine, and HDL cholesterol show promise for non-invasive AMD screening</li>
                    <li>The NEI provides a Risk Calculator for eye professionals, but it is group-based and cannot predict individual outcomes</li>
                    <li>AI-powered screening can identify patients at risk of rapid AMD progression</li>
                    <li>52 genetic variants across 34 loci are linked to AMD, though genetic testing alone is not yet recommended clinically</li>
                    <li>A multimodal approach combining biomarkers, imaging, and AI offers the best predictive accuracy</li>
                    <li>Early intervention with AREDS 2 supplements can reduce progression risk by approximately 25%</li>
                    <li>No blood-based AMD screening test is currently available to the public&mdash;this represents a significant unmet medical need</li>
                </ul>
            </div>
        </div>

        <!-- CTA Section -->
        <div class="cta-section">
            <h2>Continue Learning</h2>
            <p>Explore our educational resources to understand AMD, its risk factors, and the proactive health care approach to preserving your vision.</p>
            <div class="cta-links">
                <a href="what-is-proactive-health.html" class="cta-link primary">What is Proactive Health Care?</a>
                <a href="risk-factors.html" class="cta-link secondary">AMD Risk Factors &amp; Prevention</a>
            </div>
        </div>

        <!-- Section 10: Sources & References -->
        <div class="section">
            <h2>Sources &amp; References</h2>
            <p>This content is based on peer-reviewed research from the National Institutes of Health and the National Eye Institute:</p>

            <ul class="resource-links">
                <li>
                    <a href="https://www.nei.nih.gov/learn-about-eye-health/healthy-vision/get-dilated-eye-exam" target="_blank" rel="noopener">Get a Dilated Eye Exam</a>
                    <span class="resource-desc">National Eye Institute (NEI)</span>
                </li>
                <li>
                    <a href="https://www.nei.nih.gov/research/clinical-trials/advanced-amd-risk-calculator" target="_blank" rel="noopener">Advanced AMD Risk Calculator</a>
                    <span class="resource-desc">National Eye Institute (NEI)</span>
                </li>
                <li>
                    <a href="https://www.nei.nih.gov/about/news-and-events/news/ai-based-systems-can-help-identify-rapidly-advancing-age-related-macular-degeneration" target="_blank" rel="noopener">AI-Based Systems for Rapidly Advancing AMD</a>
                    <span class="resource-desc">National Eye Institute (NEI)</span>
                </li>
                <li>
                    <a href="https://www.nei.nih.gov/research-and-training/research-news/strategy-prevent-age-related-macular-degeneration-identified" target="_blank" rel="noopener">Strategy to Prevent AMD Identified (ApoM Research)</a>
                    <span class="resource-desc">National Eye Institute (NEI)</span>
                </li>
                <li>
                    <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10640447/" target="_blank" rel="noopener">Biomarkers for the Progression of Intermediate AMD</a>
                    <span class="resource-desc">PMC &mdash; National Institutes of Health</span>
                </li>
                <li>
                    <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2000850/" target="_blank" rel="noopener">Genetic Markers and Biomarkers for AMD</a>
                    <span class="resource-desc">PMC &mdash; National Institutes of Health</span>
                </li>
                <li>
                    <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7155063/" target="_blank" rel="noopener">Risk Factors for Progression of AMD</a>
                    <span class="resource-desc">PMC &mdash; National Institutes of Health</span>
                </li>
                <li>
                    <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12399543/" target="_blank" rel="noopener">Biomarker-Based Predictive Models in Proactive Health Management</a>
                    <span class="resource-desc">PMC &mdash; National Institutes of Health</span>
                </li>
                <li>
                    <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11143646/" target="_blank" rel="noopener">Biomarkers for Personalised Prevention of Chronic Diseases</a>
                    <span class="resource-desc">PMC &mdash; National Institutes of Health</span>
                </li>
                <li>
                    <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6396346/" target="_blank" rel="noopener">Early Detection and Prevention</a>
                    <span class="resource-desc">PMC &mdash; National Institutes of Health</span>
                </li>
            </ul>
        </div>

    </main>

    <!-- FOOTER -->
    <footer class="footer">
        <div class="footer-inner">
            <div class="footer-copyright">&copy; 2026 A1 Diagnosis. All rights reserved.</div>
            <div class="footer-links">
                <a href="index.html">Home</a>
                <a href="what-is-proactive-health.html">Proactive Health Care</a>
                <a href="early-risk-assessment.html">Early Risk Assessment</a>
                <a href="what-is-amd.html">What is AMD?</a>
                <a href="amd-stages.html">AMD Stages &amp; Treatments</a>
                <a href="risk-factors.html">Risk Factors &amp; Prevention</a>
            </div>
            <div class="footer-disclaimer">
                <strong>Medical Disclaimer:</strong> The information provided on this page is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional for medical questions or concerns. A1 Diagnosis content has not been evaluated or approved by the FDA. This information does not replace professional medical care.
            </div>
        </div>
    </footer>

</body>
</html>
